NKGNNKGen Biotech, Inc.

Nasdaq nkgenbiotech.com


$ 1.32 $ 0.06 (4.65 %)    

Wednesday, 08-May-2024 15:44:54 EDT
QQQ $ 439.55 $ -0.26 (-0.06 %)
DIA $ 390.50 $ 1.74 (0.45 %)
SPY $ 517.10 $ 0.05 (0.01 %)
TLT $ 90.18 $ -0.55 (-0.61 %)
GLD $ 213.58 $ -0.63 (-0.29 %)
$ 1.35
$ 1.30
$ 0.00 x 0
$ 0.00 x 0
$ 1.28 - $ 1.32
$ 0.78 - $ 12.88
49,031
na
20.83M
$ -0.05
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 04-16-2024 12-31-2023 10-K
2 11-14-2023 09-30-2023 10-Q
3 08-14-2023 06-30-2023 10-Q
4 05-15-2023 03-31-2023 10-Q
5 03-31-2023 12-31-2022 10-K
6 11-14-2022 09-30-2022 10-Q
7 08-15-2022 06-30-2022 10-Q
8 05-16-2022 03-31-2022 10-Q
9 03-31-2022 12-31-2021 10-K
10 11-15-2021 09-30-2021 10-Q
11 08-16-2021 06-30-2021 10-Q
12 07-02-2021 03-31-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles
Market-Moving News for April 29th
04/29/2024 12:46:23

TSLA: 14% | Tesla shares are trading higher on reports the company will partner with Baidu for mapping and navigation for Full ...

 nkgen-biotech-announces-fda-clearance-of-ind-application-for-snk01-nk-cell-therapy-in-parkinsons-disease

NKGen advances its neurodegenerative disease program with FDA IND clearance for its Phase 1/2a SNK01 Clinical Trial in patients...

 whats-going-on-with-nano-cap-nkgen-biotech-stock-on-monday

Latest on NKGen Biotech Inc (NASDAQ: NKGN) as shares surge 25.2% on high volume. Insights into NK cell therapy for neurodegener...

 nkgen-biotech-announces-upcoming-presentation-on-snk01-nk-cell-therapy-in-neurodegenerative-disease-at-the-12th-annual-alzheimers--parkinsons-drug-development-summit

NKGen Biotech, Inc. (NASDAQ:NKGN) ("NKGen" or the "Company"), a clinical-stage biotechnology company focused on...

 nkgen-biotech-presents-additional-phase-1-clinical-trial-data-in-alzheimers-disease-at-the-tau2024-global-conference

SNK01 autologous NK cell therapy demonstrated a positive effect on cerebral spinal fluid ("CSF") and plasma Tau protein...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION